Sangamo Therapeutics (SGMOQ) Research & Development (2010 - 2025)

Sangamo Therapeutics has reported Research & Development for 16 years, with the latest figure at $31.4 million in Q4 2025.

• On a quarterly basis, Research & Development rose 32.79% year-over-year to $31.4 million in Q4 2025; TTM through Dec 2025 was $112.7 million, a 1.03% increase from a year earlier, with the FY2025 full-year figure at $112.7 million, up 1.03% from the prior year.
• Research & Development was $31.4 million for Q4 2025 at Sangamo Therapeutics, up from $28.1 million in the prior quarter.
• The five-year high for Research & Development was $66.2 million in Q4 2022, with the low at $23.7 million in Q4 2024.
• Average Research & Development over 5 years is $46.9 million, with a median of $54.1 million recorded in 2021.
• The sharpest annual moves came in 2021 and 2024: Research & Development jumped 44.71% in 2021, then slumped 61.58% in 2024.
• Over 5 years, Research & Development stood at $51.8 million in 2021, then advanced by 27.76% to $66.2 million in 2022, then slipped by 23.38% to $50.7 million in 2023, then slumped by 53.31% to $23.7 million in 2024, then surged by 32.79% to $31.4 million in 2025.
• The last three Research & Development figures came in at $31.4 million (Q4 2025), $28.1 million (Q3 2025), and $27.1 million (Q2 2025), per Business Quant data.